Infectious diseases

#Automation / robotics #Drug discovery #iiCON: Infection Innovation Consortium #Infectious diseases #Lab automation

How iiCON is accelerating global infectious disease R&D

iiCON at the heart of infectious disease research   This year, a new AI robotic laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases was announced in Liverpool UK.   The £20 million ($26.4 million) Liverpool Accelerate Laboratory was developed through the Infection Innovation Consortium: iiCON – an initiative dedicated to advancing pioneering… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Drug discovery #Infectious diseases #Lab automation #Organoids #UK

New robotic AI lab opens in Liverpool to help fight infectious diseases  

The UK’s first high-security robotic AI laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases has opened in Liverpool.   The £20 million Liverpool Accelerate Laboratory has been developed through the Infection Innovation Consortium: iiCON, which advances pioneering infection R&D through collaboration between industry, researchers and the NHS. It… Read More

#News

Testing antiviral vaccines in the lab
#Antivirals #Covid-19 treatment #Ebola virus #Infectious diseases #Pneumonia #University of Queensland #Viral infections #Virus treatment

The lightbulb moment behind a potential antiviral breakthrough 

An unexpected observation by a University of Queensland (UQ) researcher could lead to a new treatment for deadly infectious diseases including Covid‑19, pneumonia in infants and children, or viral infections caused by Ebola and hantavirus.   UQ’s Australian Institute for Bioengineering and Nanotechnology neuroscientist and biochemist Dr… Read More

#News

Map of Europe
#Europe #iiCON: Infection Innovation Consortium #Infectious diseases

European network established to improve infectious disease response

A pan-European network has been established by iiCON: the Infection Innovation Consortium to help harmonise Europe’s response to infectious disease threats. iiCON secured funding from COST (European Cooperation in Science and Technology) to establish a pan-European COST Action network with over 70 collaborators from 21 countries and international organisations. The… Read More

#Business & Investment #News

#Bacteria #Gut microbiome #Infectious diseases #Inflammatory diseases

Engineered gut bacteria could be viable alternative to FMT

An engineered gut bacteria therapy could be an alternative to foecal microbiota transplants (FMT), researchers say.  Results from a Phase Ib clinical study demonstrate comparable safety and efficacy between stool-based FMT and manufactured live biotherapeutic product (LBP).  Scientists at the Icahn School of Medicine at Mount Sinai, New York developed the… Read More

#News

#Infectious diseases #Pandemic prevention #University of Texas

Research collaboration to ‘strengthen pandemic preparedness’ 

Life science company ProImmune has announced a collaboration with The University of Texas Medical Branch (UTMB) to partner on research into infectious diseases.  The collaboration will combine ProImmune’s Ankyron target binding reagent technology with expertise at the Galveston National Laboratory (GNL), part of UTMB, in the immunopathology of emerging viruses.   Under the… Read More

#News

#Autoimmune disease #Drug discovery #Infectious diseases

Asahi Kasei Pharma strengthens drug discovery pipeline 

Asahi Kasei Pharma has announced a global license agreement with Alchemedicine to strengthen its drug discovery pipeline.  The agreement means Asahi Kasei Pharma can research, develop, manufacture, and commercialise Alchemedicine’s novel lead compounds, which are currently at the preclinical stage.  The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP1 and are expected to have therapeutic potential for multiple… Read More

#Business & Investment #News

#Bill & Melinda Gates Foundation #Biologics #Evotec #Funding #Infectious diseases #Monoclonal antibodies

Grant supports Evotec’s AI-driven optimisation of mAbs

Evotec subsidiary Just – Evotec Biologics has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilising its molecular design suite of computational technologies, called J.MD.  The investment continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of… Read More

#Business & Investment #News

#Circio Holding #Infectious diseases #University of Texas

Circio to collaborate with UTMB to treat infectious diseases 

Biotechnology company Circio Holding is set to collaborate with The University of Texas Medical Branch (UTMB) to evaluate treatments for infectious diseases.  The partnership aims to design and test Circio’s circVEC technology for the prevention and treatment of infections, cancer and gene therapy. The technology allows for the long-term expression of proteins, protecting against dangerous viral pathogens.  … Read More

#Business & Investment #News

Covid-19 vaccine
#Covid-19 #DNA technology #Drug discovery #Immunology / Virology & Vaccines #Infectious diseases

The potential of DNA platforms for infectious disease vaccines 

Stacy R. Lindborg, President and Chief Executive Officer of IMUNON, discusses why research is needed to inform better strategies for infectious diseases such as Covid-19 and a new, multivalent non-viral DNA approach to vaccine development that has the potential to address continued unmet needs in the field.  Vaccines have long… Read More

#Exclusive Content

Vaccine
#Clinical trials #Drug discovery #Infectious diseases #Vaccines

Research programme represents a “new frontier in vaccine science” 

The UK’s University of Oxford, through its strategic partnership with the Ellison Institute of Technology (EIT), has received research funding of £118 ($159.7) million to launch an ambitious new programme of vaccine research.  Led by the Oxford Vaccine Group, the new initiative based in the University – CoI-AI (Correlates of… Read More

#Business & Investment #News

DNA sequencing
#Antibiotics #Bacteria #DNA #Gene sequencing #Infectious diseases #MHRA

DNA sequencing diagnoses bacterial infections faster

Scientists have developed a DNA sequencing approach that can be implemented in hospitals to diagnose bacterial infections faster and more accurately.  Developed by a UK team from Barts Health NHS Trust and the Medicines and Healthcare products Regulatory Agency (MHRA), the service is designed to help doctors… Read More

#Editor's Choice #News

#Immunology / Virology & Vaccines #Infectious diseases #Pandemic prevention #Pandemic response

Preparing for the next infectious disease pandemic

Dr Owain Millington, Chief Executive Officer at ILC Therapeutics, explores some of the areas of unmet need in infectious disease, and where the search for pleiotropic, broad-spectrum antivirals could lead drug development. Introduction Whilst the Covid-19 pandemic caused a step change in global investment for infectious diseases, there remains significant… Read More

#Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Heidelberg Pharma #Infectious diseases

ADCs: The next generation of targeted therapies 

Antibody drug conjugates (ADCs) are among the hottest properties in pharma, powerful anticancer drugs that target tumours and deliver a lethal payload that destroys them, while leaving healthy tissues untouched. But there’s much more to come from this technology. DDW’s Megan Thomas explores the topic and speaks with experts in… Read More

#Exclusive Content #Opinion #Regulatory

#AI #Career #Clinical trials #Drug discovery #Infectious diseases #Meet the Researcher #Oncology #Poolbeg Pharma

Meet the researcher: Liam Tremble

DDW’s Megan Thomas looks at a day in the life of Liam Tremble, Principal Scientist at Poolbeg Pharma. 1. Where do you work, and can you tell us what you’re working on at the moment?   I work at Poolbeg Pharma, where we are developing novel treatments for diseases with unmet… Read More

#Exclusive Content #Opinion

#Antivirals #Dermatology #Fundraising #ILC Therapeutics #Infectious diseases

ILC Therapeutics raises £2.5m to develop hybrid interferons

Glasgow, UK-based ILC Therapeutics has successfully completed a fundraise of £2.5 ($3.2) million. The company develops hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications. The money will support the continued pre-clinical development of the company’s two lead assets, Alfacyte and Dermacyte, as they move… Read More

#Business & Investment #News